We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
pharmaceuticals: Archive
Regeneron (REGN) Dupixent Gets FDA Nod for Asthma in Children
by Zacks Equity Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent secures FDA approval to treat children aged 6-11 years with moderate to severe asthma.
REGNPositive Net Change SNYNegative Net Change RHHBYPositive Net Change NVONegative Net Change
biotechs medical pharmaceuticals
Radius (RDUS) Up On Positive Data From Breast Cancer Study
by Zacks Equity Research
Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.
REGNPositive Net Change LLYNegative Net Change AMGNNegative Net Change RDUSPositive Net Change
medical pharmaceuticals
FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses
by Indrajit Bandyopadhyay
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.
JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change
messenger-rna pharmaceuticals
Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
REGNPositive Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
AZNPositive Net Change RHHBYPositive Net Change BMYNegative Net Change MRKNegative Net Change
biotechs pharmaceuticals
Top Analyst Reports for Microsoft, Mastercard & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Mastercard Incorporated (MA), and Pfizer Inc. (PFE).
MSFTPositive Net Change CVXNegative Net Change MANegative Net Change PFENegative Net Change MRKNegative Net Change PEPNegative Net Change
business-services computers consumer-staples finance oil-energy pharmaceuticals
Biotech Stock Roundup: BIIB's Q3 Earnings, REGN's COVID-19 Cocktail Update & More
by Zacks Equity Research
Regulatory and pipeline updates from bigwigs like Regeneron (REGN) and Biogen (BIIB) have been the biotech sector's few key highlights during the past week.
REGNPositive Net Change AZNPositive Net Change BIIBPositive Net Change GILDNegative Net Change AVIRNegative Net Change VALNPositive Net Change
biotechs pharmaceuticals vaccines
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
BIIBPositive Net Change SAGEPositive Net Change VTGNNegative Net Change RLMDPositive Net Change
pharmaceuticals
Markets Flat as Q3 Earnings Continue: VZ, ABT, TSLA & More
by Mark Vickery
Markets are flat in this morning's pre-market Hump Day, following a nice string of daily outperformance across indexes.
NEEPositive Net Change ABTPositive Net Change VZNegative Net Change TSLAPositive Net Change
alt-energy auto-tires-trucks communications earnings energy pharmaceuticals
Roche (RHHBY) 9M21 Sales Grow on Strong COVID-19 Tests, View Up
by Zacks Equity Research
Roche (RHHBY) posts an encouraging performance in the third quarter and the first nine months of 2021 driven by demand for coronavirus tests due to the Delta variant and recovery in pharma sales.
REGNPositive Net Change RHHBYPositive Net Change PFENegative Net Change ABBVNegative Net Change
earnings pharmaceuticals
Valneva (VALN) Reports Positive Data From COVID Vaccine Study
by Zacks Equity Research
Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.
AZNPositive Net Change PFENegative Net Change MRNAPositive Net Change VALNPositive Net Change
biofuels medical pharmaceuticals vaccines
Esperion (ESPR) to Cut 40% Workforce, Revamp Cost Structure
by Zacks Equity Research
Esperion (ESPR) is set reduce its workforce by 40% and start targeted program savings to reduce its operational expense and deliver consistent growth.
REGNPositive Net Change MRKNegative Net Change AMGNNegative Net Change ESPRNegative Net Change
pharmaceuticals
J&J (JNJ) Beats on Q3 Earnings, Misses on Sales, Ups EPS View
by Zacks Equity Research
J&J (JNJ) reports mixed third-quarter earnings. It beats estimates for earnings but misses the same for sales. It raises its earnings guidance range for the year.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
pharmaceuticals
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients
by Zacks Equity Research
Gilead (GILD) wins FDA approval for the label expansion of HIV treatment Biktarvy for the pediatric patient population.
REGNPositive Net Change GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
pharmaceuticals
Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib
by Zacks Equity Research
The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.
PFENegative Net Change LLYNegative Net Change INCYNegative Net Change ABBVNegative Net Change
medical pharmaceuticals
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's (GILD) application for breast cancer drug gets positive opinion for approval from EMA's CHMP.
REGNPositive Net Change GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechs pharmaceuticals
Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication
by Zacks Equity Research
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.
AZNPositive Net Change RHHBYPositive Net Change BMYNegative Net Change MRKNegative Net Change
pharmaceuticals
J&J, Moderna COVID-19 Booster Jabs Near FDA Authorization
by Zacks Equity Research
The FDA's Vaccines and Related Biological Products advisory committee recommends emergency use authorization for booster doses of J&J and Moderna's COVID-19 vaccines for use in certain adults.
JNJNegative Net Change PFENegative Net Change MRNAPositive Net Change BNTXPositive Net Change
messenger-rna pharmaceuticals
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change
pharmaceuticals
Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline
by Zacks Equity Research
Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
BIIBPositive Net Change RHHBYPositive Net Change BMYNegative Net Change PRTAPositive Net Change
biotechs pharmaceuticals
Exelixis (EXEL) Well Poised on Label Expansions of Caboemtyx
by Zacks Equity Research
The going has been good for Exelixis (EXEL) on label expansions of its lead drug, Cabometyx. The pipeline progress has been encouraging as well.
RHHBYPositive Net Change BMYNegative Net Change BAYRYNegative Net Change EXELNegative Net Change
biotechs pharmaceuticals
Incyte's (INCY) Going Gets Rough Despite Recent Approvals
by Zacks Equity Research
Incyte (INCY) recent drug approvals fail to impress investors due to the FDA's warnings about increased risks of serious heart-related events, cancer, blood clots, and death for JAK inhibitors.
BMYNegative Net Change PFENegative Net Change INCYNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Merck (MRK) Seeks Emergency Nod for Oral Antiviral COVID-19 Pill
by Zacks Equity Research
Merck's (MRK) molnupiravir to be the first oral antiviral medicine for the treatment of COVID-19, if authorized by the FDA.
RHHBYPositive Net Change PFENegative Net Change MRKNegative Net Change AVIRNegative Net Change
pharmaceuticals
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
JPMNegative Net Change NKEPositive Net Change PFENegative Net Change DALPositive Net Change COSTPositive Net Change MRNAPositive Net Change FDXNegative Net Change
airlines biotechs communications finance pharmaceuticals retail transportation
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
JNJNegative Net Change AMGNNegative Net Change ABBVNegative Net Change ALPNNegative Net Change IMABPositive Net Change BVSNegative Net Change
biotechs pharmaceuticals